

SUPPLEMENTAL TABLES AND FIGURES

Supplemental Table 1. Hazard ratios for clinical outcomes in participants with ABPM-ATRH and White coat-ATRH compared to No ATRH

Outcome	Unadjusted HR (95% CI)	Model A HR (95% CI)	Model B HR (95% CI)	Model C HR (95% CI)
Composite of Myocardial infarction, stroke, peripheral arterial disease, heart failure, and all-cause mortality				
ABPM-ATRH	2.38 (1.89, 2.99)	2.06 (1.62, 2.61)	1.49 (1.16, 1.92)	1.16 (0.87, 1.53)
White coat-ATRH	1.28 (0.65, 2.52)	1.1 (0.55, 2.17)	0.81 (0.4, 1.62)	0.76 (0.36, 1.59)
Heart Failure				
ABPM-ATRH	3.56(2.47, 5.12)	3.23(2.21, 4.73)	2.12(1.41, 3.18)	1.42(0.91, 2.2)
White coat-ATRH	2.13(0.84, 5.37)	1.71(0.67, 4.38)	1.1(0.42, 2.87)	0.86(0.3, 2.48)
Stroke				
ABPM-ATRH	1.58 (0.79, 3.16)	1.35 (0.65, 2.79)	0.91 (0.42, 1.97)	0.92 (0.39, 2.18)
White coat-ATRH	2.22 (0.51, 9.61)	1.61 (0.36, 7.26)	1.53 (0.32, 7.32)	2.17 (0.44, 10.81)

Model A: adjusted for age, gender, race and clinical center

Model B: adjusted for model A plus diabetes, smoking status, history of cardiovascular disease, BMI, and hemoglobin

Model C: adjusted for model B plus eGFR and Urine Protein/Creatinine Ratio, 24Hour and Spot measure combined

ABPM-ATRH, apparent treatment resistant hypertension by ABPM criteria or use of more than 3 antihypertensive medications; White coat-ATRH, apparent treatment resistant hypertension by office BP but not by ABPM criteria

Supplemental Table 2. Sensitivity analysis – ATRH definition based on average 24 hour blood pressure thresholds by ABPM

Hazard ratios for clinical outcomes in participants with ABPM-ATRH and White coat-ATRH compared to No ATRH

Outcome	Unadjusted HR (95% CI)	Model A HR (95% CI)	Model B HR (95% CI)	Model C HR (95% CI)
Composite of myocardial infarction, stroke, peripheral arterial disease, heart failure				
ABPM-ATRH	2.83 (2.02, 3.96)	2.40 (1.69, 3.42)	1.52 (1.06, 2.2)	1.03 (0.67, 1.57)
White coat-ATRH	1.54 (0.62, 3.85)	1.14 (0.45, 2.89)	0.79 (0.31, 2.04)	0.71 (0.25, 2.01)
Kidney outcome:				
ABPM-ATRH	3.64 (2.57, 5.17)	3.33 (2.31, 4.79)	2.91 (2, 4.22)	1.35 (0.85, 2.14)
White coat-ATRH	4.83 (2.56, 9.1)	3.87 (2.01, 7.43)	4.13 (2.12, 8.05)	3.30 (1.58, 6.86)
All-cause mortality				
ABPM-ATRH	2.88 (1.98, 4.21)	2.38 (1.6, 3.54)	1.83 (1.2, 2.78)	1.44 (0.88, 2.35)
White coat-ATRH	0 (0, .)*	0 (0, .)*	0 (0, .)*	0 (0, .)*

*Note: there were no patients with White Coat-ATRH who were deceased at the end of the study.

Model A: adjusted for age, gender, race and clinical center

Model B: adjusted for model A plus diabetes, smoking status, history of cardiovascular disease, BMI, and hemoglobin

Model C: adjusted for model B plus eGFR and Urine Protein/Creatinine Ratio

Kidney outcomes - 50% decrease in eGFR or end-stage renal disease defined as renal transplantation or start of long-term renal dialysis

ABPM-ATRH, apparent treatment resistant hypertension by ABPM criteria or use of more than 3 antihypertensive medications; White coat-ATRH, apparent treatment resistant hypertension by office BP but not by ABPM criteria

Definitions based on average 24-hour BP thresholds by ABPM

ABPM-ATRH: Mean office systolic BP \geq 140 mm Hg or diastolic BP \geq 90 mm Hg AND Average 24 hr ABPM systolic BP \geq 130 mm Hg or diastolic BP \geq 80 mm Hg in patients taking \geq 3 anti-hypertensive medications

OR

Apparent treatment resistant hypertension based on the use of more than 3 antihypertensive medications: Mean office systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg AND average 24 hr ABPM systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg in patients taking > 3 anti-hypertensive medications

White coat-ATRH: Mean office systolic BP \geq 140 mm Hg or diastolic BP \geq 90 mm Hg AND average 24 hr ABPM systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg in patients taking \geq 3 anti-hypertensive medications

No ATRH: Mean office systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg AND average 24 hr ABPM systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg in patients taking \leq 3 anti-hypertensive medications

Supplemental Table 3. Sensitivity analysis - hypertension defined by the 2017 ACC/AHA guidelines:

Hazard ratios for clinical outcomes in participants with ABPM-ATRH and white coat-ATRH compared to participants with no ATRH

Outcome	Unadjusted HR (95% CI)	Model A HR (95% CI)	Model B HR (95% CI)	Model C HR (95% CI)
Composite of myocardial infarction, stroke, peripheral arterial disease, heart failure				
ABPM-ATRH	2.73 (1.89, 3.96)	2.41 (1.63, 3.55)	1.62 (1.09, 2.41)	1.19 (0.76, 1.85)
White coat-ATRH	1.39 (0.67, 2.88)	1.22 (0.58, 2.55)	0.79 (0.37, 1.67)	0.77 (0.35, 1.7)
Kidney outcome				
ABPM-ATRH	4.14 (2.81, 6.11)	3.74 (2.5, 5.61)	3.42 (2.27, 5.17)	1.34 (0.82, 2.2)
White coat-ATRH	2.84 (1.53, 5.24)	2.43 (1.29, 4.57)	2.44 (1.29, 4.61)	1.18 (0.57, 2.46)
All-cause mortality				
ABPM-ATRH	2.92 (1.9, 4.49)	2.58 (1.64, 4.05)	2.14 (1.33, 3.44)	1.93 (1.12, 3.35)
White coat-ATRH	1.96 (0.92, 4.18)	1.79 (0.83, 3.87)	1.67 (0.76, 3.66)	1.4 (0.55, 3.6)

Model A: adjusted for age, gender, race and clinical center

Model B: adjusted for model A plus diabetes, smoking status, history of cardiovascular disease, BMI, and hemoglobin

Model C: adjusted for model B plus eGFR and Urine Protein/Creatinine Ratio

Kidney outcome-50% decrease in eGFR or end-stage renal disease defined as renal transplantation or start of long-term renal dialysis

ABPM-ATRH, apparent treatment resistant hypertension by ABPM criteria or use of more than 3 antihypertensive medications; White coat-ATRH, apparent treatment resistant hypertension by office, but not by ABPM criteria.

Definitions based on hypertension as defined by the 2017 ACC/AHA guidelines:

ABPM-ATRH: apparent treatment resistant hypertension by ABPM and office blood pressure criteria: Mean office systolic BP ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg AND Average ABPM daytime systolic BP ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg In patients taking ≥ 3 anti-hypertensive medications


OR

Apparent treatment resistant hypertension based on the use of more than 3 antihypertensive medications: Mean office systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg AND Average ABPM daytime systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg In patients taking > 3 anti-hypertensive medications

White coat-ATRH: apparent treatment resistant hypertension by office, but not by ABPM criteria: Mean office systolic BP ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg AND Average ABPM daytime systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg In patients taking ≥ 3 anti-hypertensive medications

No ATRH: Mean office systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg AND Average ABPM daytime systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg In patients taking ≤ 3 anti-hypertensive medications

Supplemental Figure 1: Flow diagram of exclusion criteria



ABPM, ambulatory blood pressure monitoring; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.